Key result
Sacubitril/valsartan is linked to a ~42% drop in NT-proBNP and higher ANP regardless of LVEF.
Why the study?
The relationship between longitudinal changes in natriuretic peptides and echocardiographic parameters across the LVEF range in patients with HF treated with sacubitril/valsartan is not fully understood.
Does sacubitril/valsartan improve natriuretic peptide levels and reverse cardiac remodeling in patients with heart failure across the LVEF spectrum?
Observational (n=49)
Does sacubitril/valsartan improve natriuretic peptide levels and reverse cardiac remodeling in patients with heart failure across the LVEF spectrum?
Sacubitril/valsartan induces favorable changes in natriuretic peptides (increased ANP, decreased NT-proBNP) and promotes reverse cardiac remodeling in heart failure patients regardless of baseline LVEF.
May support biomarker shifts with sacubitril/valsartan across LVEF; leaves open outcome benefits in prospective trials.
Sacubitril/valsartan improves outcomes in patients with heart failure (HF) with reduced ejection fraction. However, the relationship between longitudinal changes in natriuretic peptides and echocardiographic parameters in patients with HF treated with sacubitril/valsartan across the left ventricular ejection fraction (LVEF) range is not fully understood.In patients with HF treated with sacubitril/valsartan, comprehensive data on natriuretic peptides, including atrial natriuretic peptide (ANP), N-terminal pro-brain-type natriuretic peptide (NT-proBNP), BNP, and echocardiography, were measured after 6 months of treatment. We assessed the change in natriuretic peptides and echocardiographic parameters in LVEF classification subgroups.Among 49 patients, the median ANP concentration increased from 55 pg/mL at baseline to 78 pg/mL (P < 0.001). The NT-proBNP concentration decreased from 250 pg/mL to 146 pg/mL (P < 0.001). No significant change was observed in the BNP concentration (P = 0.640). The trajectories of each natriuretic peptide in patients with LVEF > 40% (n = 22) were similar to those in individuals with LVEF ≤ 40% (n = 27). Regardless of LVEF classification, echocardiography at 6 months showed a significant improvement in LVEF, left ventricular end-diastolic volume, and the ratio of early diastolic mitral inflow velocity to early diastolic mitral annulus velocity (E/e'). The reduction in natriuretic peptide concentration was related to LV reverse remodeling and decreased left and right atrial pressures assessed by E/e' and inferior vena cava diameter.Sacubitril/valsartan induced an increase in ANP, a reduction in NT-proBNP, and no change in plasma BNP, regardless of LVEF. It caused LV reverse remodeling, and the natriuretic peptide concentration changes were associated with structural and functional echocardiographic parameters.
No takes yet. Share an insight, caveat, or question.
Yamamoto et al. (2023) conducted an observational in Heart failure (n=49). Sacubitril/valsartan was evaluated on Change in natriuretic peptides (ANP, NT-proBNP, BNP) and echocardiographic parameters (p=<0.001). Sacubitril/valsartan treatment for 6 months in heart failure patients significantly increased median ANP (55 to 78 pg/mL, P<0.001) and decreased NT-proBNP (250 to 146 pg/mL, P<0.001) regardless of LVEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: